Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail as well as corporate materials mailed to you.

Recent News:

 

5/7/2012 HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2012
…..CASH USED IN OPERATIONS REDUCED AND ENHANCEMENTS TO MANUFACTURING FACILITY CONTINUE
4/30/2012 Hemispherx Biopharma Announces Test of Ampligen® with FluMist
…. First Intranasal Administration in Humans

3/26/2012 Hemispherx Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)
….Incidence of NABs Induced Against Natural IFNs, such as Alferon N Injection®, was Very Low (<0.2%) and Significantly Less than for Recombinant IFNs

3/20/2012 HEMISPHERX BIOPHARMA, INC. TO HOST 2011 YEAR END CONFERENCE CALL ON THURSDAY, MARCH 22, 2012
3/19/2012 Hemispherx Publishes Data on the Bioactivity of Ampligen® in Chronic Fatigue Syndrome (“CFS”)
Peer-Reviewed Data in Two Publications Supports the Pending NDA Application

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

 McGladrey & Pullen, LLP

 

Investor Relations:

Dianne Will
Phone:  518-398-6222
Fax:  518-398-6369
or send an e-mail to:
ir@hemispherx.net

 

 

 

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.